MediWound Ltd

Quick facts

Marketed products

• Nexobrid · Dermatology
  Nexobrid works by breaking down the eschar, a dead layer of skin, to facilitate its removal.
• NEXOBRID · Other
• NexoBrid · Wound Care / Burn Treatment
  NexoBrid is a topical enzymatic debriding agent containing bromelain that selectively removes necrotic tissue from burn wounds.

Phase 3 pipeline

• DGD · Wound Care / Burn Treatment
  DGD is a recombinant protease that selectively debrides necrotic tissue by breaking down denatured collagen and proteins in burn wounds.
• EscharEx (EX-03) · Wound Care / Burn Treatment
  EscharEx is a topical enzymatic debriding agent that selectively removes necrotic tissue from burns and wounds.

Phase 2 pipeline

• EscharEx · Wound care
  EscharEx is a topical enzyme therapy that degrades necrotic tissue.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• MediWound Ltd portfolio CI brief
• MediWound Ltd pipeline updates RSS